Chris Seeks Clarity On Vaccination Conditional Marketing Authorisation
Christopher Chope Conservative, Christchurch
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 16 November 2022 to Question 83513 on Coronavirus: Vaccination, for what reasons covid-19 vaccines which have a conditional marketing authorisation such as (a) Spikevax, Moderna, (b) Spikevax bivalent, Moderna, (c) Comirnaty bivalent, Pfizer-BioNTech and (d) Novavax, Nuvaxovid can continue to be used now that the Comirnaty vaccine has full marketing authorisation.
Maria Caulfield The Parliamentary Under-Secretary for Health and Social Care, Parliamentary Under-Secretary (Department for International Trade) (Minister for Women)
The granting of a full Marketing Authorisation for one product does not affect the Conditional Marketing Authorisations (CMA) of others. CMAs are used for products which prevent or treat serious and life-threatening diseases where no satisfactory treatment methods are available or where the product offers a significant therapeutic advantage. The Medicines and Healthcare products Regulatory Agency may grant a CMA where comprehensive clinical data is not yet complete although it is judged that such data will become available shortly.
- ENDS - #106304
To read the previous referred Written Answer please CLICK HERE
- ENDS – #83513
